Project Main Details
Please audition by reading the script below. We are looking for a warm, confident, authoritative yet conversational tone (imagine a kind doctor explaining all of this to a hopeful patient).
Thanks very much for your time!
To learn more about the treatment go to:
https://www.youtube.com/watch?v=h6SzI2ZfPd4 2015-04-15 19:18:16 GMT 2015-04-25 15:00:00 (GMT -05:00) Eastern Time (US & Canada) Yes (click here to learn more about ) Closed and fulfilled 78 68 0 direct invitation(s) have been sent by the voice seeker resulting in 0 audition(s) and/or proposal(s) so far. Voice123 SmartCast is seeking 200 auditions and/or proposals for this project (approx.) Invitations sent by SmartCast have resulted in 77 audition(s) and/or proposal(s) so far.
Researchers at the University of Pennsylvania have developed an investigational, personalized gene therapy that modifies a patient’s own T cells so that they can hunt for and possibly destroy cancerous cells.
This therapy is currently being tested in clinical trials for a variety of cancers, including leukemia and lymphoma and several types of solid tumors. All patients who receive this investigational treatment have cancers that have progressed despite multiple conventional therapies.
The investigational treatment begins by removing a patient’s own T cells, which are collected by a procedure called apheresis, very similar to dialysis. Blood flows out through one intravenous tube and is filtered through a machine to remove some of the patient’s white blood cells, while the remaining blood is returned to the body through another tube. This procedure takes about two hours.
Next, the T cells undergo a re-programming process over several days in Penn’s Clinical Cell and Vaccine Production Facility. Scientists there use a gene transfer technique designed to teach the T cells to recognize, target and kill tumor cells. The engineered cells contain an antibody-like protein known as a Chimeric Antigen Receptor (or CAR). In the case of blood cancers including B cell leukemias and lymphomas, the CAR is designed to bind to a specific protein on these cancerous B cells, called CD19.
Over the next one to two weeks, more of these engineered cells are grown in the lab. This process generates an army of tumor hunter cells. If this process is successful, hundreds of millions to billions of engineered cells are prepared for infusion back into the patient.
Several days prior to the infusion, the patient may receive chemotherapy drugs to help “make room” for the new genetically modified cells and allow them to multiply within the body.
The infusion of the genetically modified T cells is given intravenously, over just a few minutes.
Once infused into the patient, the T cells begin to search out and bind to surface proteins on tumor cells. Binding of the CAR to the target protein activates the modified T cell to kill the cancer cell, and also promotes rapid multiplication of the modified cells. Tests from patients in the trials reveal that each engineered cell can grow to more than 10,000 new cells in the patient’s body, and cancer cells which can no longer escape detection are destroyed.
Most patients who have a very high level of cancer in their bodies and have responded to the therapy so far have experienced a cytokine release syndrome (also known as CRS) within a few days after receiving their infusions. Patients who experience a CRS typically have varying degrees of flu-like symptoms, with high fevers, nausea, muscle pain, and sometimes, low blood pressure and breathing difficulties that require intensive care. Some patients require treatment with anti-cytokine drugs and steroids to manage these symptoms. At this point, many patients are admitted to the hospital for the treatment of these symptoms. This condition is a key indicator that the engineered cells have begun proliferating and killing tumor cells in the body.
Clinical trial results of this approach have shown great promise: 90 percent of patients with acute lymphocytic leukemia, or ALL, went into remission after receiving the therapy. About half of patients with chronic lymphocytic leukemia, or CLL, have benefitted from the therapy, including some who have been in remission for over four years. In July 2014, this therapy was awarded the U.S. Food and Drug Administration’s Breakthrough Therapy designation for ALL, becoming the first personalized cellular therapy for the treatment of cancer to receive this important classification.
Voice123 Team Comments
Voice123 consultations with this voice seeker regarding this project and/or other projects by this voice seeker, via phone, chat, and/or email.
This project - phone.
Previous projects - phone.
This project - email or chat.
Previous projects - email or chat.
Corporate web site for this voice-seeker confirmed by Voice123
Note: Voice123 strives to establish the legitimacy of all projects posted. However, Voice123 subscribers and users are responsible for confirming information stated by prospective voice seekers, agents and/or clients. Voice123 subscribers and users assume all liability for use of any information found through Voice123, or any of its publications.
This page contains the most important details of this project. If you find the information on this project inaccurate or inappropriate, please let us know by contacting us.